

1 **Predicting mortality attributable to SARS-CoV-2: A mechanistic**  
2 **score relating obesity and diabetes to COVID-19 outcomes in**  
3 **Mexico**

4 Omar Yaxmehen Bello-Chavolla<sup>1,2\*</sup>, Jessica Paola Bahena-López<sup>3</sup>, Neftali Eduardo Antonio-  
5 Villa<sup>1,3</sup>, Arsenio Vargas-Vázquez<sup>1,3</sup>, Armando González-Díaz<sup>4</sup>, Alejandro Márquez-Salinas<sup>2,3</sup>,  
6 Carlos A. Fermín-Martínez<sup>1,3</sup>, J. Jesús Naveja<sup>5</sup>, Carlos A. Aguilar-Salinas<sup>1,6,7</sup>

7  
8 <sup>1</sup>Unidad de Investigación de Enfermedades Metabólicas, Instituto Nacional de Ciencias  
9 Médicas y Nutrición Salvador Zubirán. <sup>2</sup>Division of Research, Instituto Nacional de Geriátria.  
10 <sup>3</sup>MD/PhD (PECEM), Faculty of Medicine, National Autonomous University of Mexico.  
11 <sup>4</sup>Universidad Nacional Autónoma de México. <sup>5</sup>Instituto de Química, Universidad Nacional  
12 Autónoma de México. <sup>6</sup>Department of Endocrinology and Metabolism. Instituto Nacional de  
13 Ciencias Médicas y Nutrición Salvador Zubirán. <sup>7</sup>Tecnológico de Monterrey, Escuela de  
14 Medicina y Ciencias de la Salud.

15 Corresponding authors

16 Carlos A. Aguilar-Salinas. Unidad de Investigación de Enfermedades Metabólicas. Instituto  
17 Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Vasco de Quiroga 15. CP  
18 14080; Tlalpan, Distrito Federal, México. Phone: +52(55)54870900, 5703. E-mail:  
19 [caguilarsalinas@yahoo.com](mailto:caguilarsalinas@yahoo.com)

20 Omar Yaxmehen Bello-Chavolla. Division of Research. Instituto Nacional Geriátria. Anillo  
21 Perif. 2767, San Jerónimo Lídice, La Magdalena Contreras, 10200, Mexico City, Mexico.  
22 Phone: +52 (55) 5548486885. E-mail: [oyaxbell@yahoo.com.mx](mailto:oyaxbell@yahoo.com.mx)

23

24 **Word count:** 3,284 words; 40 references; 2 tables; 4 figures.

25 **ABSTRACT**

26 **BACKGROUND AND AIMS:** The SARS-CoV-2 outbreak has posed a challenge to the  
27 healthcare systems due to high complications rates observed in patients with cardiometabolic  
28 diseases, such as diabetes and obesity. Despite the high prevalence of these conditions, a  
29 mechanistic association of its interactions in COVID-19 remain unclear. Here, we identify risk  
30 factors and propose a clinical score to predict 30-day lethality in COVID-19 cases, including  
31 specific factors for diabetes and obesity and its role in improving risk prediction.

32 **METHODS:** We obtained data of suspected, confirmed and negative COVID-19 cases and  
33 their demographic and health characteristics from the General Directorate of Epidemiology of  
34 Mexican Ministry of Health. We investigated specific risk factors associated to SARS-CoV-2  
35 positivity and mortality due to COVID-19. Additionally, we explored the impact of diabetes and  
36 obesity on COVID-19 related outcomes and their interaction with other comorbidities in  
37 modifying COVID-19 related lethality. Finally, we built our clinical score to predict 30-day  
38 lethality using the previously identified risk factors.

39 **RESULTS:** Among 49,570 evaluated subjects (at April 19<sup>th</sup>, 2020), we observed an increased  
40 risk of SARS-CoV-2 positivity (n=8,261) in those with diabetes, obesity, male subjects and in  
41 patients with diabetes and age <40 years (early-onset). Risk factors for increased lethality in  
42 COVID-19 includes early-onset diabetes obesity, chronic obstructive pulmonary disease,  
43 advanced age, immunosuppression, and chronic kidney disease; we also found that obesity  
44 mediates 47.8% of the effect of diabetes on COVID-19 lethality. Early-onset diabetes  
45 conferred an increased risk of hospitalization and obesity conferred an increased risk for ICU  
46 admission and intubation. Our predictive score for COVID-19 lethality included age  $\geq 65$  years,  
47 diabetes, diabetes & age <40 years, obesity, age <40 years, CKD, pregnancy and  
48 immunosuppression and a categorization of low-risk, mild-risk, moderate-risk, high-risk and

49 very high-risk significantly discriminates lethal from non-lethal COVID-19 cases (c-  
50 statistic=0.837).

51 **CONCLUSIONS:** Here, we propose a mechanistic approach to evaluate risk for complication  
52 and lethality attributable to COVID-19 in patients with obesity and diabetes patients in a  
53 country with high susceptibility. Furthermore, our novel score offers a clinical tool for quick  
54 determination of high-risk susceptibility patients in a first contact scenario.

## 55 INTRODUCTION

56 The first cases of SARS-CoV-2 infection in Mexico were reported at the end of February <sup>1</sup>;  
57 since then, the number of COVID-19 cases have been steadily increasing, with most fatal  
58 cases being associated with the presence of comorbidity and, particularly, cardiometabolic  
59 comorbidities. A high prevalence of cardiometabolic diseases worldwide represents a  
60 challenge during the COVID-19 epidemic. An elevated number of patients with SARS-CoV-2  
61 infection have a preexisting disease such as obesity, hypertension, cardiovascular disease,  
62 diabetes, chronic respiratory disease or cancer <sup>2,3</sup>. Diabetes mellitus and obesity represent a  
63 large share of the cardiometabolic morbidity burden of the region <sup>4</sup>; moreover, most cases of  
64 diabetes remain either undiagnosed or lack adequate glycemic control, posing them at risk of  
65 increased COVID-19 severity. Despite several reports evaluating the burden of comorbidities  
66 including obesity, diabetes and hypertension on the clinical course of COVID-19, the joint role  
67 of obesity and diabetes in modifying COVID-19 outcomes has not been fully explored <sup>5</sup>.  
68 Several studies have demonstrated a higher susceptibility to acute respiratory infectious  
69 diseases in people with diabetes <sup>6</sup>. Moreover, diabetes and obesity have been described as  
70 independent risk factors for severe pulmonary infection <sup>7,8</sup>. Obesity influences the clinical  
71 outcomes during an acute severe respiratory distress syndrome (ASRDS); it has been  
72 proposed as a protective factor for mortality following lung injury (due to reverse causality) or  
73 as a cause of mortality and adverse clinical outcomes for severe influenza cases (due to  
74 mechanical and immunologic factor). In the cases of the COVID-19 outbreak, obesity has  
75 been consistently associated with adverse outcomes <sup>9,10</sup>. Furthermore, a large proportion of  
76 obesity cases in Mexico lives in geographical areas of increased social vulnerability, which  
77 poses a structural inequality that might also increase mortality for COVID-19 associated to  
78 both diabetes and obesity <sup>11</sup>. Chronic inflammation in obesity might worsen the acute  
79 inflammatory response triggered by SARS-Cov2 infection, which might be associated to a  
80 cytokine release syndrome <sup>5,12</sup>. Here, we investigate the role of both diabetes and obesity in

81 determining propensity for SARS-CoV-2 infection and its associated clinical outcomes  
82 including disease severity and COVID-19 lethality; using these associations, we further  
83 construct a clinically useful predictive model for COVID-19 mortality using national  
84 epidemiological surveillance data from Mexico.

## 85 **METHODS**

### 86 Data sources

87 We extracted this dataset from the General Directorate of Epidemiology of the Mexican  
88 Ministry of Health, which is an open-source dataset comprising daily updated data of  
89 suspected COVID-19 cases which have been confirmed with a positive test for SARS-CoV-2  
90 certified by the National Institute for Diagnosis and Epidemiological Referral <sup>13</sup>.

### 91 Definitions of suspected and confirmed COVID-19 cases

92 The Ministry of Health defines a suspected COVID-19 case as an individual of any age whom  
93 in the last 7 days has presented cough, fever or headache (at least two), accompanied by  
94 either dyspnea, arthralgias, myalgias, sore throat, rhinorrhea, conjunctivitis or chest pain.  
95 Amongst these suspected cases, the Ministry of Health establishes two protocols for case  
96 confirmation: 1) SARS-CoV-2 testing is done widespread for suspected COVID-19 cases with  
97 severe acute respiratory infection with signs of breathing difficulty or deaths in suspected  
98 COVID-19 cases, 2) for all other suspected cases, a sentinel surveillance model is being  
99 utilized, whereby 475 health facilities comprise a nationally representative sample which  
100 samples ~10% of mild outpatient cases and all suspected severe acute respiratory infection  
101 <sup>14</sup>. Demographic and health data are collected and uploaded to the epidemiologic surveillance  
102 database by personnel from the corresponding individual facility.

### 103 Variables definitions

104 Available information for all confirmed, negative and suspected COVID-19 cases includes  
105 age, sex, nationality, state and municipality where the case was detected, immigration status  
106 as well as identification of individuals who speak indigenous languages from Mexico. Health

107 information includes status of diabetes, obesity, chronic obstructive pulmonary disease  
108 (COPD), immunosuppression, pregnancy, arterial hypertension, cardiovascular disease,  
109 chronic kidney disease (CKD) and asthma. Date of symptom onset, hospital admission and  
110 death are available for all cases as well as treatment status (outpatient or hospitalized),  
111 information regarding diagnosis of pneumonia, ICU admission and whether the patient  
112 required invasive mechanical ventilation.

### 113 Statistical analysis

#### 114 *Comorbidities associated to SARS-CoV-2 positivity*

115 We investigated the association of demographic and health data associated with SARS-CoV-  
116 2 positivity using logistic regression analyses, excluding individuals who were only suspected  
117 but unconfirmed cases of COVID-19. Next, we stratified these analyses for individuals with  
118 only diabetes or only obesity to identify specific risk factors within these populations,  
119 especially focusing on individuals who were <40 years and likely acquired the disease early.

#### 120 *COVID-19 mortality risk*

121 In order to investigate risk factors predictive of COVID-19 related 30-day lethality, we fitted  
122 Cox Proportional risk regression models estimating time from symptom onset up to death or  
123 censoring, whichever occurred first in cases with confirmed positivity for SARS-CoV-2. To  
124 identify diabetes and obesity-specific risk factors, we carried out stratified analyses. Given the  
125 availability of SARS-CoV2 negative cases within the dataset, we fitted Cox models for 30-day  
126 mortality which included SARS-CoV-2 positivity as an interaction term with different  
127 comorbidities, hypothesizing that some factors increase mortality risk specifically for COVID-  
128 19. Finally, we fitted a logistic regression model only for mortality cases to evaluate  
129 associations with lethality rates in COVID-19 related and non-related deaths.

#### 130 *Influence of obesity and diabetes in COVID-19 related outcomes*

131 Finally, we estimated factors associated to admission to hospital facilities, intensive care units  
132 (ICUs) and requirements for mechanical ventilation in all confirmed COVID-19 cases using

133 Poisson regression, considering as the offset the log-transformed time from symptom onset  
134 to hospital admission. To identify specific factors for all COVID-19 and non-COVID-19  
135 patients related to outcomes, we included interaction effects with comorbidities factors; we  
136 also performed Kaplan-Meier analyses to identify the role of comorbidities in modifying  
137 lethality risk in individuals with diabetes and obesity and compared across categories using  
138 Breslow-Cox tests. Finally, we performed causal-mediation analyses with causally-ordered  
139 mediators using a previously validated approach to investigate whether obesity mediates the  
140 decreases COVID-19 survival attributable to diabetes, particularly in early-onset cases <40  
141 years<sup>15</sup>.

#### 142 *Mechanistic mortality risk score for COVID-19*

143 Finally, we constructed a clinically useful model to predict 30-day mortality in COVID-19  
144 cases that might be useful to apply in primary care facilities, including variables and  
145 interactions which were identified in mortality analyses. Points were assigned by  
146 standardizing all  $\beta$  coefficients with the minimum absolute  $\beta$  coefficient obtained from Cox  
147 regression. Points were stratified according to categories of Low risk ( $\leq 0$ ), Mild risk (1-3),  
148 Moderate risk (4-6), High risk (7-9) and very high risk ( $\geq 10$ ). Risk across categories was  
149 verified using Kaplan-Meier analyses. C-statistics and  $D_{xy}$  values were corrected for over-  
150 optimism using k-fold cross-validation (k=10) using the *rms* R package. A p-value <0.05 was  
151 considered as statistical significance threshold. All analyses were performed using R software  
152 version 3.6.2.

## 153 **RESULTS**

### 154 *COVID-19 cases in Mexico*

155 At the time of writing this report (April 19<sup>th</sup>, 2020), a total of 49,570 subjects had been treated  
156 initially as suspected COVID-19 cases. Amongst them, 8,261 had been confirmed with as  
157 positive and 31,170 tested negatives for SARS-CoV-2 infection; additionally, 10,139 cases  
158 were still being studied as suspected cases pending testing reports. Amongst confirmed

159 cases, 686 deaths were reported (8.3%) whilst 490 deaths were SARS-CoV-2 negative cases  
160 (1.6%) and 112 deaths of suspected but unconfirmed cases (1.1%) had been reported.  
161 Compared to SARS-CoV-2 negative cases, confirmed cases were older, predominantly male  
162 (58%, 1.37:1 ratio), had higher rates of hospitalization and showed a higher prevalence of  
163 diabetes (16.7% vs. 10.3%), hypertension (20.6% vs. 15.1%) and obesity (19.4% vs. 13.5%),  
164 but less CKD (2.0% vs. 2.1%). SARS-CoV-2 cases were also more likely to be treated as  
165 inpatients and had higher rates of ICU admission and requirements for invasive ventilation  
166 **(Table 1)**.

#### 167 *Factors associated with COVID-19 positivity*

168 We investigated cases related to COVID-19 positivity within Mexico. We found that risk of  
169 SARS-CoV-2 positivity was higher with diabetes, obesity and male sex **(Figure 1)**. When  
170 assessing age, we observed reduced odds of SARS-CoV-2 positivity in patients younger than  
171 age 40 and, in contrast, when exploring its interaction with type 2 diabetes, we observed an  
172 increased probability of SARS-CoV-2 infection. In stratified models, we observed that for  
173 patients with diabetes, SARS-CoV-2 positivity was associated with obesity, male sex and an  
174 interaction effect was observed between obesity and having less than 40 years; for patients  
175 with obesity, diabetes and male sex were also significant.

#### 176 *Predictors for COVID-19 related 30-day mortality*

177 We identified that COVID-19 cases were associated with a two-fold increase in mortality due  
178 to acute respiratory infection (HR 2.361, 95%CI 2.020-2.759) compared to non-COVID-19  
179 cases. Of interest, the only comorbidity which conferred increased lethality risk exclusively for  
180 COVID-19 compared to non-COVID-19 was obesity (HR 1.746, 95%CI 1.278-2.385, **Figure**  
181 **1A**). Factors associated to increased lethality in COVID-19 cases were age >65 years,  
182 diabetes mellitus, obesity, CKD, COPD, immunosuppression **(Figure 1B)**. We searched for  
183 an interaction between diabetes mellitus and age <40 years adjusted for sex and obesity; a

184 higher mortality risk was found for early onset diabetes cases (HR 2.968, 95%CI 1.929-  
185 4.565).

#### 186 *COVID-19 in patients with diabetes mellitus*

187 Confirmed COVID-19 cases with diabetes has a mean age of 56.9 ( $\pm$ 12.9) years and were  
188 predominantly male. This population had particularly higher proportions of mortality (19.1%  
189 vs. 6.2%), hospitalization and confirmed pneumonia compared with those without diabetes.  
190 When stratifying mortality for those with early onset diabetes (<40 years), general diabetic  
191 population and elder patients, we found a mortality rate of 6.8%, 51% and 42.2%,  
192 respectively. As expected, obesity, hypertension, COPD, CKD, CVD, immunosuppression  
193 and asthma were also more prevalent in this population. Interestingly, we observed no  
194 significant differences in ICU admission and requirements for mechanical ventilation between  
195 subjects with and without diabetes (**Supplementary table 1**). In patients with diabetes  
196 mellitus, COVID-19 related 30-day mortality was higher in those with concomitant  
197 immunosuppression, COPD, CKD and those aged >65 years (**Figure 1C**). When assessing  
198 the role of comorbidities, COVID-19 patients with diabetes, coexistent obesity, those with  
199 early onset diabetes (<40 years) or an increase in the number of comorbidities had increased  
200 risk of COVID-19 lethality (Breslow test  $p < 0.001$ , **Figure 2**). When comparing cases with and  
201 without COVID-19 amongst patients with diabetes mellitus, only obesity displayed a  
202 significant interaction with COVID-19 (HR 1.663 95%CI 1.093-2.528) with diabetes after  
203 adjustment for age, sex and comorbidities (**Supplementary Figure 2**).

#### 204 *COVID-19 in patients with obesity*

205 Similar to patients with diabetes, confirmed COVID-19 cases with obesity had particularly  
206 higher proportions of mortality (13.6% vs. 6.7%), hospitalization and confirmed pneumonia.  
207 Furthermore, patients with obesity also had higher rates of ICU admission (7.2% vs. 4.2%)  
208 and were more likely to be intubated (6.9% vs. 4%). As expected, diabetes, hypertension,  
209 COPD, smoking, CVD and asthma were also more prevalent in patients with obesity

210 **(Supplementary table 2)**. As previously mentioned, obesity was identified as a risk factor  
211 which displayed differential risk for COVID-19 infection, specific risk factors for lethality in  
212 obese patients with COVID-19 infection immunosuppression and age >65 (**Figure 1D**);  
213 overall, COVID-19 increased risk of mortality in obesity seven-fold (HR 7.56, 95%CI 5.79-  
214 9.87). The addition of obesity to any number of comorbidities significantly increased the risk  
215 for 30-day COVID-19 lethality (Breslow test  $p < 0.001$ , **Figure 2-C**). Using causally ordered  
216 mediation analysis we investigated whether the effect of diabetes (E) on COVID-19 related  
217 30-day lethality was partially mediated by obesity (M); the direct effect of diabetes on COVID-  
218 19 lethality was significant ( $\Delta_{E1 \rightarrow Y} = 1.84$ , 95%CI: 1.56-2.17) as was the indirect effect of  
219 obesity ( $\Delta_{M1 \rightarrow Y} = 1.68$ , 95%CI: 1.45-1.99), representing 47.8% of the total effect of diabetes.

#### 220 *COVID-19 outcomes and comorbidities*

221 Given the increased risk of diabetes and obesity in modifying COVID-19 related lethality, a  
222 secondary objective of our study was to investigate its associations with inpatient outcomes,  
223 including hospitalization rate, ICU admission and requirement for mechanical ventilation. In  
224 general, early-onset diabetes patients and those with obesity had higher risk of  
225 hospitalization, whilst patients with obesity also had increased risk for ICU admission and  
226 required intubation. Patients with diabetes mellitus overall had higher risk of hospitalization  
227 with no significant additional risk of ICU admission and intubation (**Figure 3**).

#### 228 *Mechanistic score for mortality in COVID-19*

229 Using the identified predictors for mortality and the observed interaction for early-onset  
230 diabetes, we designed a predictive score for 30-day COVID-19 mortality using Cox  
231 regression. We identified as significant predictors age >65 years, diabetes mellitus, obesity,  
232 CKD, COVID-19 related pneumonia, COPD, pregnancy and immunosuppression (**Table 2**);  
233 age <40 was a protective factor which was modified by its interaction with T2D ( $R^2 = 0.166$ , C-  
234 statistic 0.837,  $D_{xy} = 0.675$ ); assigning the point system ); assigning the point system did not  
235 significantly reduce the model's performance ( $R^2 = 0.165$ , C-statistic = 0.837,  $D_{xy} = 0.674$ ).

236 Finally, category stratification reduced only moderately performance statistics ( $R^2=0.162$ , C-  
237 statistic=0.823,  $D_{xy}=0.643$ ), and were not significantly modified after cross-validation  
238 correction ( $R^2=0.188$ ,  $D_{xy}=0.644$ ). Distribution of the score significantly discriminates between  
239 lethal and non-lethal COVID-19 cases (**Figure 4**).

240

## 241 **DISCUSSION**

242 Our results demonstrate that diabetes, particularly early onset diabetes mellitus, obesity and  
243 comorbidity burden modify risk profiles in patients with COVID-19 infection in Mexico and  
244 significantly improve mortality prediction related to COVID-19 lethality. These findings  
245 position the notion that early-onset type 2 diabetes might carry a higher risk of mortality in  
246 younger patients, which is similar to older patients with comorbidities and only higher in older  
247 patients with diabetes. Furthermore, our results suggest that obesity is a COVID-19 specific  
248 risk factor for mortality, risk of ICU admission, tracheal intubation and hospitalization and  
249 even increases risk in patients with diabetes and COVID-19 infection. Overall, this positions  
250 the co-existence of obesity and diabetes, particularly early-onset diabetes, as a considerable  
251 risk factor for COVID-19 mortality in Mexicans, whom have reported an alarmingly high  
252 burden of both conditions in recent health surveys.

253 The relationship between increased risk of mortality attributable to acute severe respiratory  
254 infections in patients with diabetes mellitus has been extensively reported, particularly for the  
255 acute respiratory syndrome caused by SARS-CoV-1<sup>16-18</sup>. Evidence relating SARS-CoV-2  
256 infections in China demonstrated increased rates of diabetes mellitus in hospitalized patients  
257 and in those with increased disease severity as assessed by ICU admission and requirement  
258 for invasive ventilation. Additionally, hospitalized patients have shown increased rates of both  
259 obesity and diabetes for COVID-19 compared to non-hospitalized cases in the US, China and  
260 Italy<sup>5,19,20</sup>. Increased susceptibility for COVID-19 in patients with diabetes may be explained  
261 for several potential mechanisms including an increased lung ACE2 expression and elevated  
262 circulating levels of furin, a protease involved in viral entry to cells, and a decreased  
263 clearance of SARS-CoV-2 viral particles in subjects with diabetes and/or hypertension  
264 associated with ACE2 expression<sup>21-24</sup>. Impairments in immunity observed in patients with  
265 diabetes are characterized by initial delay in activation of Th1 cell-mediated immunity and late  
266 hyper-inflammatory response and are consistent with the increased risk associated with

267 additional immunosuppression observed with our data <sup>25</sup>. Additional factors which have been  
268 proposed to modify COVID-19 mortality risk and worsen glycemic control in diabetes include  
269 corticosteroid therapy, inadequate glucose monitoring, the effect of social distancing on  
270 diabetes care and the use of antihypertensive medication; however these factors remain to  
271 be confirmed by clinical evidence <sup>26</sup>. Given the large proportion of undiagnosed diabetes  
272 cases in Mexican and poor glycemic control reported by recent estimates, the burden of  
273 COVID-19 might be higher than expected in Mexico and poses a challenge for the Mexican  
274 healthcare system to give particular attention to this sector as the epidemic moves forward  
275 <sup>27-29</sup>.

276 Diabetes mellitus is one of the main causes of morbidity and it accounts for a large proportion  
277 of mortality risk in Mexican population <sup>4</sup>. Of relevance, Mexicans have increased risk of  
278 diabetes and diabetes-related obesity attributable to genetic variants associated to its  
279 Amerindian ancestry, and an earlier age of onset independent of body-mass index <sup>30,31</sup>. Data  
280 on the incidence of early-onset type 2 diabetes in Mexican population position obesity and  
281 insulin resistance as significant risk factors, which are also highly prevalent in younger  
282 patients and increase metabolic risk <sup>32,33</sup>. These associations partly explain the increased risk  
283 of COVID-19 lethality in younger patients within our cohort despite the younger average age  
284 of Mexican population and poses early-onset diabetes mellitus as a significant risk factor for  
285 COVID-19 mortality and increased severity of infection in younger patients <sup>5,34</sup>.

286 In our work, we demonstrate that compared to non-COVID-19 infections, obesity significantly  
287 modifies the risk of mortality attributable to COVID-19 infection. Obesity and, in particular,  
288 abdominal obesity, is one of Mexico's main public health problems; in recent years the socio-  
289 economic burden of obesity as well as its impact on mortality have increased drastically, with  
290 the Ministry of Health declaring a state of epidemiological emergency <sup>35</sup>. Evidence from  
291 different regions has supported the notion that obesity increases mortality risk and severity of  
292 COVID-19 infections, which holds particularly true for younger patients <sup>2,36</sup>. Obesity is

293 characterized by a low-grade state of inflammation and may impair immune response which  
294 in turn also may affect the lung parenchyma, increasing the risk for inflammatory lung  
295 diseases<sup>37,38</sup>. In particular, abdominal obesity reduces the compliance of lung, chest wall and  
296 entire respiratory system, resulting in impaired ventilation of the base of the lungs and  
297 reduced oxygen saturation of blood<sup>39</sup>. Recently, Simonnet et al. explored the high prevalence  
298 of obesity in patients with COVID-19 reporting that obesity is a risk factor for SARS-CoV-2  
299 infection severity independent of age, diabetes and hypertension. Notably, ACE2 expression  
300 in adipose tissue is higher than in the lung and its expression profile is not different in obese  
301 and non-obese subjects; however, obese subjects have more adipocytes; thus, they have a  
302 greater number of ACE2-expressing cells and thus higher likelihood of SARS-CoV-2 entry  
303<sup>2,40</sup>. Our data shows that obesity is a specific risk factor for COVID-19 related outcomes and  
304 that it partly mediates the risk associated with diabetes mellitus. Public health efforts by the  
305 Mexican government in epidemiological surveillance have largely focused in identifying  
306 patient's at highest risk of complications; these findings could inform public health decisions  
307 and increase awareness on the role of obesity in modifying risk of COVID-18 outcomes.

308 Our study had some strengths and limitations. First, we analyzed a large dataset which  
309 included information on both confirmed positive and negative SARS-CoV-2 cases, which  
310 provides a unique opportunity to investigate COVID-19 specific risk factors and develop a  
311 predictive model for COVID-19 mortality. Additionally, with the database being nationally-  
312 representative it allows for reasonable estimates on the impact of both diabetes and obesity  
313 despite the possibility of important regional differences in cardiometabolic risk which might  
314 influence risk estimates. A potential limitation of this study is the use of data collected from a  
315 sentinel surveillance system model, which is skewed towards investigating high risk cases or  
316 only those with specific risk factors which on one hand increases power to detect the effect of  
317 comorbidities and on the other hand might not be representative of milder cases of the  
318 disease; this is demonstrated in the risk of COVID-19 positivity, which is higher for high risk

319 cases. The updating daily estimates of COVID-19 cases are unlikely to change the direction  
320 of the identified associations though it might modify numeric estimates. Implementation of our  
321 proposed model might be useful to allocate prompt responses to high risk cases and improve  
322 stratification of disease severity.

323 In conclusion, we show that both diabetes and obesity increase the risk of SARS-CoV-2  
324 infection in Mexico. In particular, diabetes increases the risk of COVID-19 related mortality  
325 and, specifically, increases mortality risk in early-onset cases. Obesity is a COVID-19 specific  
326 risk factor for mortality and for increased disease severity; obesity also is a partial mediator  
327 on the effect of diabetes in decreasing survival associated with COVID-19 infection. This  
328 mechanistic interpretation on the risk of comorbidities allowed the development of a model  
329 with good performance to predict mortality in COVID-19 cases. Given the burden of obesity  
330 and diabetes in Mexico, COVID-19 lethality might be higher in younger cases. Special  
331 attention should be given to susceptible individuals and screening should be conducted for all  
332 symptomatic cases with either obesity and/or diabetes to decrease the burden associated  
333 with COVID-19 in Mexico.

334

### 335 **ACKNOWLEDGMENTS**

336 JPBL, AVV, NEAV, AMS and CAFM are enrolled at the PECEM program of the Faculty of  
337 Medicine at UNAM. JPBL and AVV are supported by CONACyT. The authors would like to  
338 acknowledge the invaluable work of all of Mexico's healthcare community in managing the  
339 COVID-19 epidemic. Its participation in the COVID-19 surveillance program has made this  
340 work a reality, we are thankful for your effort.

### 341 **DATA AVAILABILITY**

342 All data sources and R code are available for reproducibility of results at  
343 [https://github.com/oyaxbell/covid\\_diabetesmx](https://github.com/oyaxbell/covid_diabetesmx).

### 344 **AUTHOR CONTRIBUTIONS**

345 Research idea and study design OYBC, JPBL, CAAS; data acquisition: OYBC, AGD; data  
346 analysis/interpretation: OYBC, JPBL, NEAV, AVV, AGD, JJN, CAAS; statistical analysis:  
347 OYBC, NEAV; manuscript drafting: OYBC, NEAV, AVV, JPBL, AMS, CAFM, JJN; supervision  
348 or mentorship: OYBC, CAAS. Each author contributed important intellectual content during  
349 manuscript drafting or revision and accepts accountability for the overall work by ensuring  
350 that questions pertaining to the accuracy or integrity of any portion of the work are  
351 appropriately investigated and resolved.

352 **FUNDING:** No funding was received.

353 **CONFLICT OF INTEREST/FINANCIAL DISCLOSURE:** Nothing to disclose.

## 354 REFERENCES

- 355 1 Información Internacional y Nacional sobre nuevo Coronavirus (COVID-2019) | Secretaría  
356 de Salud | Gobierno | gob.mx. [https://www.gob.mx/salud/documentos/informacion-](https://www.gob.mx/salud/documentos/informacion-internacional-y-nacional-sobre-nuevo-coronavirus-2019-ncov)  
357 [internacional-y-nacional-sobre-nuevo-coronavirus-2019-ncov](https://www.gob.mx/salud/documentos/informacion-internacional-y-nacional-sobre-nuevo-coronavirus-2019-ncov) (accessed April 19, 2020).
- 358 2 Simonnet A, Chetboun M, Poissy J, *et al.* High prevalence of obesity in severe acute  
359 respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical  
360 ventilation. *Obesity (Silver Spring)* 2020; published online April 9. DOI:10.1002/oby.22831.
- 361 3 Zhou F, Yu T, Du R, *et al.* Clinical course and risk factors for mortality of adult inpatients  
362 with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020; **395**: 1054–  
363 1062.
- 364 4 Bello-Chavolla OY, Rojas-Martinez R, Aguilar-Salinas CA, Hernández-Avila M.  
365 Epidemiology of diabetes mellitus in Mexico. *Nutr Rev* 2017; **75**: 4–12.
- 366 5 Grasselli G, Zangrillo A, Zanella A, *et al.* Baseline Characteristics and Outcomes of 1591  
367 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.  
368 *JAMA* 2020; published online April 6. DOI:10.1001/jama.2020.5394.
- 369 6 Muller LMAJ, Gorter KJ, Hak E, *et al.* Increased risk of common infections in patients with  
370 type 1 and type 2 diabetes mellitus. *Clin Infect Dis* 2005; **41**: 281–288.

- 371 7 Van Kerkhove MD, Vandemaele KAH, Shinde V, *et al.* Risk factors for severe outcomes  
372 following 2009 influenza A (H1N1) infection: a global pooled analysis. *PLoS Med* 2011; **8**:  
373 e1001053.
- 374 8 Luzi L, Radaelli MG. Influenza and obesity: its odd relationship and the lessons for  
375 COVID-19 pandemic. *Acta Diabetol* 2020; published online April 5. DOI:10.1007/s00592-  
376 020-01522-8.
- 377 9 Jose RJ, Manuel A. Does COVID-19 Disprove the Obesity Paradox in ARDS? *Obesity*  
378 (*Silver Spring*) 2020; published online April 15. DOI:10.1002/oby.22835.
- 379 10 Dietz W, Santos-Burgoa C. Obesity and its Implications for COVID-19 Mortality. *Obesity*  
380 (*Silver Spring*) 2020; published online April 1. DOI:10.1002/oby.22818.
- 381 11 Shamah-Levy T, Campos-Nonato I, Cuevas-Nasu L, *et al.* [Overweight and obesity in  
382 Mexican vulnerable population. Results of Ensanut 100k]. *Salud Publica Mex* 2019; **61**:  
383 852–865.
- 384 12 Moore BJB, June CH. Cytokine release syndrome in severe COVID-19. *Science* 2020; :  
385 eabb8925.
- 386 13 Datos Abiertos - Dirección General de Epidemiología | Secretaría de Salud | Gobierno |  
387 gob.mx. <https://www.gob.mx/salud/documentos/datos-abiertos-152127?idiom=es>  
388 (accessed April 18, 2020).
- 389 14 Secretaría de Salud Subsecretaría de Prevención y Promoción de la Salud Dirección  
390 General de Epidemiología. LINEAMIENTO ESTANDARIZADO PARA LA VIGILANCIA  
391 EPIDEMIOLÓGICA Y POR LABORATORIO DE LA ENFERMEDAD RESPIRATORIA  
392 VIRAL. 2020.
- 393 15 Cho S-H, Huang Y-T. Mediation analysis with causally ordered mediators using Cox  
394 proportional hazards model. *Stat Med* 2019; **38**: 1566–1581.

- 395 16 Yang JK, Feng Y, Yuan MY, *et al.* Plasma glucose levels and diabetes are independent  
396 predictors for mortality and morbidity in patients with SARS. *Diabet Med* 2006; **23**: 623–  
397 628.
- 398 17 Bello-Chavolla OY, Bahena-Lopez JP, Garciadiego-Fosass P, *et al.* Bloodstream infection  
399 caused by *S. aureus* in patients with cancer: a 10-year longitudinal single-center study.  
400 *Support Care Cancer* 2018; **26**: 4057–4065.
- 401 18 Akbar DH. Bacterial pneumonia: comparison between diabetics and non-diabetics. *Acta*  
402 *Diabetol* 2001; **38**: 77–82.
- 403 19 CDC COVID-19 Response Team. Preliminary Estimates of the Prevalence of Selected  
404 Underlying Health Conditions Among Patients with Coronavirus Disease 2019 - United  
405 States, February 12-March 28, 2020. *MMWR Morb Mortal Wkly Rep* 2020; **69**: 382–386.
- 406 20 Liang W-H, Guan W-J, Li C-C, *et al.* Clinical characteristics and outcomes of hospitalised  
407 patients with COVID-19 treated in Hubei (epicenter) and outside Hubei (non-epicenter): A  
408 Nationwide Analysis of China. *Eur Respir J* 2020; published online April 8.  
409 DOI:10.1183/13993003.00562-2020.
- 410 21 Chen X, Hu W, Ling J, *et al.* Hypertension and Diabetes Delay the Viral Clearance in  
411 COVID-19 Patients. *medRxiv* 2020; published online March 24.  
412 DOI:10.1101/2020.03.22.20040774.
- 413 22 Rao S, Lau A, So H-C. Exploring diseases/traits and blood proteins causally related to  
414 expression of ACE2, the putative receptor of 2019-nCov: A Mendelian Randomization  
415 analysis. *medRxiv* 2020; published online March 8. DOI:10.1101/2020.03.04.20031237.
- 416 23 Fernandez C, Rysä J, Almgren P, *et al.* Plasma levels of the proprotein convertase furin  
417 and incidence of diabetes and mortality. *J Intern Med* 2018; **284**: 377–387.
- 418 24 Wrapp D, Wang N, Corbett KS, *et al.* Cryo-EM structure of the 2019-nCoV spike in the  
419 prefusion conformation. *Science* 2020; **367**: 1260–1263.

- 420 25 Hodgson K, Morris J, Bridson T, Govan B, Rush C, Ketheesan N. Immunological  
421 mechanisms contributing to the double burden of diabetes and intracellular bacterial  
422 infections. *Immunology* 2015; **144**: 171–185.
- 423 26 Klonoff DC, Umpierrez GE. COVID-19 in patients with diabetes: risk factors that increase  
424 morbidity. *Metab Clin Exp* 2020; : 154224.
- 425 27 Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence,  
426 pathophysiology, prognosis and practical considerations. *Diabetes Metab Syndr* 2020; **14**:  
427 303–310.
- 428 28 Campos-Nonato I, Ramírez-Villalobos M, Flores-Coria A, Valdez A, Monterrubio-Flores E.  
429 Prevalence of previously diagnosed diabetes and glycemic control strategies in Mexican  
430 adults: ENSANUT-2016. *PLoS One* 2020; **15**: e0230752.
- 431 29 Puig-Domingo M, Marazuela M, Giustina A. COVID-19 and endocrine diseases. A  
432 statement from the European Society of Endocrinology. *Endocrine* 2020; published online  
433 April 11. DOI:10.1007/s12020-020-02294-5.
- 434 30 SIGMA Type 2 Diabetes Consortium, Williams AL, Jacobs SBR, *et al*. Sequence variants  
435 in SLC16A11 are a common risk factor for type 2 diabetes in Mexico. *Nature* 2014; **506**:  
436 97–101.
- 437 31 Almeda-Valdes P, Gómez Velasco DV, Arellano Campos O, *et al*. The SLC16A11 risk  
438 haplotype is associated with decreased insulin action, higher transaminases and large-  
439 size adipocytes. *Eur J Endocrinol* 2019; **180**: 99–107.
- 440 32 Arellano-Campos O, Gómez-Velasco DV, Bello-Chavolla OY, *et al*. Development and  
441 validation of a predictive model for incident type 2 diabetes in middle-aged Mexican  
442 adults: the metabolic syndrome cohort. *BMC Endocr Disord* 2019; **19**: 41.
- 443 33 Aguilar-Salinas CA, Rojas R, Gómez-Pérez FJ, *et al*. Prevalence and characteristics of  
444 early-onset type 2 diabetes in Mexico. *Am J Med* 2002; **113**: 569–574.

- 445 34 Jiménez-Corona A, Rojas R, Gómez-Pérez FJ, Aguilar-Salinas CA. Early-onset type 2  
446 diabetes in a Mexican survey: results from the National Health and Nutrition Survey 2006.  
447 *Salud Publica Mex* 2010; **52 Suppl 1**: S27–35.
- 448 35 Nieto C, Tolentino-Mayo L, Monterrubio-Flores E, *et al.* Nutrition Label Use Is Related to  
449 Chronic Conditions among Mexicans: Data from the Mexican National Health and Nutrition  
450 Survey 2016. *J Acad Nutr Diet* 2019; published online Oct 1.  
451 DOI:10.1016/j.jand.2019.07.016.
- 452 36 Lighter J, Phillips M, Hochman S, *et al.* Obesity in patients younger than 60 years is a risk  
453 factor for Covid-19 hospital admission. *Clin Infect Dis* 2020; published online April 9.  
454 DOI:10.1093/cid/ciaa415.
- 455 37 Huttunen R, Syrjänen J. Obesity and the risk and outcome of infection. *Int J Obes* 2013;  
456 **37**: 333–340.
- 457 38 Zhang X, Zheng J, Zhang L, *et al.* Systemic inflammation mediates the detrimental effects  
458 of obesity on asthma control. *Allergy Asthma Proc* 2017; published online Oct 2.  
459 DOI:10.2500/aap.2017.38.4096.
- 460 39 Dixon AE, Peters U. The effect of obesity on lung function. *Expert Rev Respir Med* 2018;  
461 **12**: 755–767.
- 462 40 Jia X, Yin C, Lu S, *et al.* Two Things about COVID-19 Might Need Attention. 2020;  
463 published online Feb 23. DOI:10.20944/preprints202002.0315.v1.
- 464

465 **Table 1.** Descriptive statistics comparing negative, positive and suspected cases for SARS-CoV-2 in Mexico at 04/19/2020.  
 466 *Abbreviations:* ICU= intense care unit; COPD= chronic obstructive pulmonary disease; CKD= chronic kidney disease; CVD=  
 467 cardiovascular disease.

Parameter	Negative for SARS-CoV-2 (N=31,170)	Positive for SARS-CoV-2 (N=8,261)	Suspected for SARS-CoV-2 (N=10,139)
Age (years)	39.37±17.72	46.32±15.70	41.41±17.04
Male sex (%)	14396 (46.2)	4789 (58.0)	5121 (50.5)
Mortality (%)	490 (1.6)	686 (8.3)	112 (1.1)
Hospitalization (%)	6398 (20.5)	3049 (36.9)	2263 (22.3)
Pneumonia (%)	4096 (13.1)	2307 (27.9)	1459 (14.4)
ICU admission (%)	507 (1.6)	398 (4.8)	161 (1.6)
Invasive ventilation (%)	435 (1.4)	378 (4.6)	107 (1.1)
Diabetes (%)	3207 (10.3)	1380 (16.7)	1329 (13.1)
COPD (%)	893 (2.9)	222 (2.7)	232 (2.3)

Asthma (%)	1744 (5.6)	290 (3.5)	519 (5.1)
Immunosuppression (%)	956 (3.1)	161 (1.9)	221 (2.2)
Hypertension (%)	4721 (15.1)	1700 (20.6)	1883 (18.6)
Obesity (%)	4220 (13.5)	1605 (19.4)	1626 (16.0)
CKD (%)	700 (2.1)	161 (2.0)	249 (2.5)
CVD (%)	1056 (3.4)	250 (3.0)	335 (3.3)
Smoking (%)	3306 (10.6)	761 (9.2)	1035 (10.2)

---

468

469

470 **Table 2.** Cox proportional risk models for lethality using the mechanistic COVID-19 lethality score in confirmed cases of COVID-19  
 471 using individual components, single score point and risk stratification categories. Abbreviations: COPD= chronic obstructive  
 472 pulmonary disease; CKD= chronic kidney disease; CVD= cardiovascular disease.


Model	Parameter	B	Score	SE	Wald	HR	95% CI	P Value
Individual variables <i>C-statistic= 0.837</i>	Age ≥65 years	0.612	2	0.085	7.238	1.84	1.56-2.18	<0.001
	Diabetes mellitus	0.256	1	0.086	2.982	1.29	1.09-1.53	0.003
	Diabetes & Age <40 years	1.140	4	0.317	3.598	3.13	1.68-5.81	<0.001
	Obesity	0.446	2	0.08394	5.310	1.56	1.32-1.84	<0.001
	Age <40 years	-1.419	-6	0.17330	-8.19	0.24	0.17-0.40	<0.001
	CKD	0.718	2	0.15423	4.65	2.05	1.52-2.77	<0.001
	Pneumonia	1.800	7	0.094	19.18	6.05	5.03-7.27	<0.001
	COPD	0.406	2	0.138	2.95	1.50	1.14-1.96	0.003
	Pregnancy	1.703	7	0.459	3.71	5.49	2.23-13.48	<0.001
Immunosuppression	0.505	2	0.175	2.888	1.66	1.17-2.33	0.004	

Score point	1-Point increment	0.253426	0.00858	29.55	1.29	1.27-1.31	<0.001
<i>C-statistic= 0.837</i>							
	Low-Risk (0 pts)			Reference			
	Mild-Risk (1-3 pts)	1.94	0.175	11.07	6.95	4.93-9.80	<0.001
Risk Categories	Moderate-Risk (4-6 pts)	2.73	0.230	11.88	15.41	9.81-24.20	<0.001
<i>C-statistic= 0.823</i>							
	High-Risk (7-9 pts)	3.14	0.159	19.73	23.02	16.86-31.45	<0.001
	Very High-Risk (≥10 pts)	3.87	0.163	23.71	48.08	34.91-66.21	<0.001

473

474

475 **FIGURE LEGENDS**



476


477 **Figure 1.** Cox proportional risk regression analysis to evaluate lethality of SARS-CoV-2 in Mexico, compared to SARS-CoV2 negative

478 cases for all suspected cases with SARS-CoV2 status available (A) and stratified by diabetes mellitus (B) and obesity (C).

479 *Abbreviations:* ICU= intense care unit; COPD= chronic obstructive pulmonary disease; CKD= chronic kidney disease; CVD=

480 cardiovascular disease, HR= Hazard ratio.

481




482

483 **Figure 2.** Kaplan-Meier survival curves to evaluate lethality of SARS-CoV-2 positivity in patients with diabetes and comorbidities (A),

484 diabetes and obesity (B), obesity and comorbidities (C) and diabetes with age 40 years (D). Abbreviations: DM= Diabetes

485 mellitus; OB= Obesity; Comorb= Comorbidities.




486

487 **Figure 3.** Logistic regression analyses to evaluate COVID-19 related outcomes in all patients with SARS-CoV2 positivity for

488 admission to ICU (A), mechanical ventilation (B) and hospital admission risk (C).

489



490

491

**Figure 4.** Symptom onset among lethal and non-lethal cases in new-confirmed COVID 19 cases, stratified by diabetes and obesity

492

status (A), density histogram of scores of the mechanistic COVID-19 score (B). Points and score intervals considered for clinical

493

score scale (C) and Kaplan-Meier Survival analysis curves to evaluate lethality using risk categories (D). Abbreviations: OB=

494

Obesity; DM= Diabetes mellitus; CKD= chronic kidney disease; COPD= Chronic obstructive pulmonary disease.